Skip to content
  • Learn More
  • Publications
  • Team
  • Contact Us
Menu
  • Learn More
  • Publications
  • Team
  • Contact Us

PRISM will be accepting submissions for our next screen May 27 – June 13!

DMSO-soluble small molecules (single agent and combination format) and single agent antibodies, ADCs, and growth-inhibiting cytokines will be accepted for our 930 cancer cell line screen.

Contact us to learn more

Miss our team at AACR 2025? Check out our poster presentations!

Dozens of non-oncology drugs can kill cancer cells

PRISM Logo in White

The Broad Institute of MIT and Harvard
75 Ames Street
Cambridge, MA 02142

PRISM@BroadInstitute.org

Join our newsletter to stay up to date with PRISM.

Copyright © 2023. All Rights Reserved.

Conference Posters + Abstracts:
AACR 2025

  • PRISM cancer cell viability profiling enables insights into clinical candidate target selectivity: A case study revealing the most selective PRMT5 inhibitors for cancers with MTAP loss – Abstract | Poster
  • Accelerating the development of biologics: PRISM high throughput screening enables rapid preclinical characterization of antibodies, ADCs and payloads – Abstract | Poster
  • A cellular platform for systematic comparison of RAS inhibitors using PRISM multiplexed screening – Abstract | Poster